• Home
  • A-B index
  • Pharmacological Index
  • Drug Classes
  • Active Ingredients
  • Companies
  • News
  • Stunarone
    / Janssen

    Active Ingredient
    Cinnarizine 25 mg

    Status in Israel

    Presentation and Status in Health Basket

    Presentation Basket Yarpa Pharmasoft


    25 X 25 mg

    full basket chart 22301 19399

    Related information


    Disorders of balance: In adults: 1 tablet of 25 mg t.i.d.
    Motion sickness: in adults: 1 tablet of 25 mg half an hour before traveling; to be repeated every 6 hours.
    Children (5-12): half of the adult dose is recommended.
    STUNARONE should preferably be taken after meals.


    Symptomatic treatment of nausea and vertigo due to Meniere’s disease and
    other labyrinthine disturbances and for travel sickness.


    STUNARONE is contraindicated in patients with known hypersensitivity to the drug.

    Special Precautions

    As with other antihistamines STUNARONE may cause epigastric distress; taking it after meals may diminish gastric irritation.In patients with Parkinson’s disease STUNARONE should only be given if the advantages outweigh the possible risk of aggravating this disease. STUNARONE may cause somnolence, especially at the start of treatment. Therefore caution should be taken when alcohol or CNS depressants are used concomitantly. Use of cinnarizine should be avoided in porphyria. There have been no specific studies in hepatic or renal dysfunction. Stugeron should be used with care in patients with hepatic or renal insufficiency. Patients with rare hereditary problems of fructose or galactose intolerance, the Lapp lactase deficiency, glucose-galactose malabsorption or sucrase-isomaltase insufficiency, should not take this medicine because it contains lactose and sucrose.

    Side Effects

    For full details see prescribing information.

    Drug interactions

    Alcohol , CNS depressants and Tricyclic Antidepressants: Concurrent use of alcohol, CNS depressants or tricyclic antidepressants may potentiate the sedative effects of either of these medications or of STUNARONE.
    Diagnostic Interference: Because of its antihistamine effect, STUNARONE may prevent otherwise positive reactions to dermal reactivity indicators if used up to 4 days prior to skin testing.

    Pregnancy and Lactation

    Use during pregnancy: The safety of Stugeron in human pregnancy has not been established although studies in animals have not demonstrated teratogenic effects. As with other drugs it is not advisable to administer Stugeron in pregnancy.
    Use during lactation: There are no data on the excretion of STUNARONE in human breast milk: nursing should therefore be discouraged in women using STUNARONE.


    Symptoms: The signs and symptoms are mainly due to the anticholinergic (atropine-like) activity of cinnarizine.
    Acute cinnarizine overdoses have been reported with doses ranging from 90 to 2,250 mg. The most commonly reported signs and symptoms associated with overdose of cinnarizine include: alterations in consciousness ranging from
    somnolence to stupor and coma, vomiting, extrapyramidal symptoms, and hypotonia. In a small number of young children, seizures developed. Clinical consequences were not severe in most cases, but deaths have been reported after single and polydrug overdoses involving cinnarizine.
    Treatment: There is no specific antidote. For any overdose, the treatment is symptomatic and supportive care.
    Activated charcoal should only be considered in patients presenting within one hour of taking a potentially toxic overdose (ie more than 15mg/kg).

    Janssen Cilag S.P.A., Italy
    Licence holder